[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487163":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":62,"collaborators":32,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":32,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":32,"overallStatus":84,"whyStopped":32,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Southern California","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","DHM 300mg x1 dose",[13],"Drug: Dihydromyricetin",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","DHM 900mg x1 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","DHM 300mg x1 dose + Lysine 140mg x1 dose",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","DHM 900mg x1 dose + Lysine 420mg x1 dose",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Dihydromyricetin","Dose-escalation and lysine preparation",[9,15,19,23],null,[34],{"name":35,"affiliation":5,"role":36},"Brian Lee, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":32,"email":41},"CONTACT","323-442-5576","brian.lee@med.usc.edu",[43],{"facility":5,"status":32,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Los Angeles","California","90089","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-118.24368,34.05223,{"lat":53,"lon":52},[56,58,61],{"name":35,"role":39,"phone":57,"phoneExt":32,"email":41},"866-797-2770",{"name":59,"role":39,"phone":57,"phoneExt":32,"email":60},"Matthew Dukewich, MD","matthew.dukewich@med.usc.edu",{"name":59,"role":39,"phone":32,"phoneExt":32,"email":32},{"type":36,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Brian P. Lee","Assistant Professor of Medicine","100487163","phase-1-phase-i-dose-escalation-study-of-dihydromyricetin-dhm-to-treat-alcohol-associated-liver-disease-100487163",false,"NCT05623501","Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease","Inclusion Criteria:\n\n* No prior medical history of alcohol use disorder or alcohol-associated liver disease\n* Between 18-60 years old\n\nExclusion Criteria:\n\n* Weight below 50kg.\n* Advanced liver disease\n* Other acute liver diseases\n* HIV co-infection\n* History of pancreatic or biliary disease\n* Acute illness that would interfere with drug absorption\n* Pregnancy\n* Participants who are currently taking drugs with CYP3A4 effects\n* FIB-4 Index \\> 1.30\n* History of Alcohol Use Disorder (AUD) determined by score \\> 8 on AUDIT questionnaire",true,"ALL","18 Years","60 Years",{"count":76,"type":77},12,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).",[83],"Alcohol-Related Disorders","NOT_YET_RECRUITING","2024-08-28",{"date":87,"type":88},"2024-09-03","ACTUAL",{"date":90,"type":77},"2024-09-15",{"date":92,"type":77},"2025-12-31",{"name":5,"class":6},1]